

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371</b>		ATTORNEY'S DOCKET NUMBER <b>057878-000024</b>  U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>To be assigned</b>
INTERNATIONAL APPLICATION NO. <b>PCT/IL2004/000732</b>	INTERNATIONAL FILING DATE <b>05 August 2004 (5.08.2004)</b>	PRIORITY DATE CLAIMED <b>07 August 2003 (7.08.2003)</b>
TITLE OF INVENTION METHOD FOR THE PURIFICATION OF A NON-IMMUNOGLOBULIN PROTEIN COMPRISING AN IMMUNOGLOBULIN-LIKE (IG-LIKE) DOMAIN		
APPLICANT(S) FOR DO/EO/US APPLIED RESERACH SYSTEMS ARS HOLDING N.V.; SCHWARTSBURD, Boris and RISHON-LE-ZION, Ilana		

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☐ This is a **FIRST** submission of items concerning a submission under 35 U.S.C. 371.
2. ☒ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a submission under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☐ The US has been elected (Article 31).
5. ☐ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☐ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

**Items 11 to 20 below concern document(s) or information included:**

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A preliminary amendment.
14. ☐ An Application Data Sheet under 37 CFR 1.76.
15. ☐ A substitute specification.
16. ☐ A power of attorney and/or change of address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.
18. ☐ A second copy of the published International Application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) <b>To be assigned</b>	INTERNATIONAL APPLICATION NO. <b>PCT/IL2004/000732</b>	ATTORNEY'S DOCKET NUMBER <b>057878-000024</b>	
20. Other items or information: <b>Certificate of Mailing; COPY-References B1-B3 and C1-C43 and Return Receipt Postcard</b>			
The following fees have been submitted		CALCULATIONS	PTO USE ONLY
21. <input type="checkbox"/> Basic national fee (37 CFR 1.492(a))..... <b>\$300</b>		\$	
22. <input type="checkbox"/> Examination fee (37 CFR 1.492(c))		\$	
If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)..... <b>\$0</b> All other situations..... <b>\$200</b>		\$	
23. <input type="checkbox"/> Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the International preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)..... <b>\$0</b> Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority..... <b>\$100</b> International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB..... <b>\$400</b> All other situations..... <b>\$500</b>		\$	
<b>TOTAL OF 21, 22 and 23 =</b>			0.00
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)). The fee is <b>\$250</b> for each additional 50 sheets of paper or fraction thereof.			
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE
- 100 =	/50 =		x \$250
			\$ 0.00
Surcharge of <b>\$130.00</b> for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h)).		\$	0.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	- 20 =		x \$ 50
Independent claims	- 3 =		x \$200
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$360
<b>TOTAL OF ABOVE CALCULATIONS =</b>		\$	0.00
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by ½.			0.00
<b>SUBTOTAL =</b>		\$	0.00
Processing fee of <b>\$130.00</b> for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).		\$	0.00
<b>TOTAL NATIONAL FEE =</b>		\$	0.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property		\$	0.00
<b>TOTAL FEES ENCLOSED =</b>		\$	0.00
		Amount to be refunded:	\$
		Amount to be charged	\$

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

- a. ☐ A check in the amount of \$ \_\_\_\_\_ to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ to cover the above fees.  
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0850. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

**NOTE:** Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.

SEND ALL CORRESPONDENCE TO:

David S. Resnick  
Nixon Peabody LLP  
100 Summer Street  
Boston, MA 02110  
US



SIGNATURE

David S. Resnick/Leena H. Karttunen

NAME

34,235

REGISTRATION NUMBER

Practitioner's Docket No. 057878-000024

PATENT

567, 422

## IN THE UNITED STATES RECEIVING OFFICE

PCT/IL2004/000732	5 August 2004 (05.08.2004)	7 August 2003 (07.08.2003)
International Application Number	International Filing Date	International Earliest Priority Date

**TITLE OF INVENTION:** METHOD FOR THE PURIFICATION OF A NON –  
IMMUNOGLOBULIN PROTEIN COMPRISING AN  
IMMUNOGLOBULIN-LIKE (IG-LIKE) DOMAIN

**APPLICANT(S) FOR EO/DO:** Applied Research Systems ARS Holding N.V.  
**INVENTOR(S)/APPLICANT(S) FOR US:** Boris SCHWARTSBURD et al.

**CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. § 1.8(a) and 1.10)**

I hereby certify that this correspondence:

1. Certificate of Mailing (1 pg.);
2. Form PTO-1390 –Transmittal Letter page 3 in duplicate (4 pp.);
3. Information Disclosure Statement with Form PTO/SB/08a and b (6 pp.);
4. Copy of References B1-B3 and C1-C43; and
5. Return Receipt Postcard.

is on the date shown below being:


**MAILING**

☒ deposited with the United States Postal Service  
with sufficient postage as first class mail in an  
envelope addressed to the  
MAIL STOP PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**FACSIMILE**

transmitted by facsimile to the Patent  
and Trademark Office.

Date: February 13, 2006

  
Signature

Rebecca J. Goodwin  
(type or print name of person certifying)

## IN THE UNITED STATES RECEIVING OFFICE

PCT/IL2004/000732	5 August 2004 (05.08.2004)	7 August 2003 (07.08.2003)
International Application Number	International Filing Date	International Earliest Priority Date

**TITLE OF INVENTION:**      **METHOD FOR THE PURIFICATION OF A NON –  
IMMUNOGLOBULIN PROTEIN COMPRISING AN  
IMMUNOGLOBULIN-LIKE (IG-LIKE) DOMAIN**

**APPLICANT(S) FOR EO/DO:**      Applied Research Systems ARS Holding N.V.  
**INVENTOR(S)/APPLICANT(S) FOR US:** Boris SCHWARTSBURD et al.

MAIL STOP PCT  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

\*\*\*\*\*

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is, on the date shown below, being: deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to MAIL STOP PCT, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Date: February 13, 2006

  
Rebecca J. Goodwin

\*\*\*\*\*

Sir:

**INFORMATION DISCLOSURE STATEMENT**

In accordance with the provisions of 37 C.F.R. §§1.56 and 1.97, Applicants herewith submit the publications and/or patents shown on the attached forms PTO/SB/08 a and b, for consideration by the Examiner in connection with the examination of the above-identified patent application.

**I. REMARKS**

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed:

- X              (1)      within three (3) months of the Filing Date or **before the mailing date of the First Office Action** on the merits; or
- (2)      within three months of the mailing date of the PCT International Search Report; or

## IN THE UNITED STATES RECEIVING OFFICE

PCT/IL2004/000732	5 August 2004 (05.08.2004)	7 August 2003 (07.08.2003)
International Application Number	International Filing Date	International Earliest Priority Date

**TITLE OF INVENTION:**                    **METHOD FOR THE PURIFICATION OF A NON-IMMUNOGLOBULIN PROTEIN COMPRISING AN IMMUNOGLOBULIN-LIKE (IG-LIKE) DOMAIN**

**APPLICANT(S) FOR EO/DO:**                    Applied Research Systems ARS Holding N.V.  
**INVENTOR(S)/APPLICANT(S) FOR US:** Boris SCHWARTSBURD et al.

- (3)            after the period defined in (1) but before the mailing date of a **Final Rejection** or **Notice of Allowance**, and the requisite Certification or fee under Rule 1.17(p), namely **\$180.00**, is included herein; or
- (4)            after the mailing date of a **Final Rejection** or **Notice of Allowance** but before the payment of the **Issue Fee**, and the requisite Certification, petition, and petition fee are included herein.

  X                      A copy of the International Search Report is enclosed herewith.

It is respectfully requested that each of the documents shown on the attached form(s) PTO/SB/08a and b be made of record in this application.

Copies of these documents (CHECK ONE):

- X                      are enclosed herewith that have not been previously submitted; or
- have been cited in the parent application, and are thus not being resubmitted herein.

Early examination and allowance of the present application are respectfully solicited.

**FEE AUTHORIZATION**

Should any fees associated with the submission be required, the Commissioner is authorized to charge the missing fee to our Deposit Account No. 50-0850. Any overpayments should be credited to said Deposit Account.

Respectfully submitted,



David S. Resnick (Reg. No. 34,235)  
Leena H. Karttunen (L0207)  
NIXON PEABODY LLP  
100 Summer Street  
Boston, MA 02110  
(617) 345-6057

Date: February 9, 2006



Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	To be assigned (371 of PCT/IL2004/000732)
				I.A. Filing Date	05 August 2004
				First Named Inventor	Boris SCHWARTSBURD
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	2	of	4	Attorney Docket Number	057878-000024

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	C1	ANDERSON, Dirk M. et al.; Nature; 390:175-179 (13 Nov. 1997)		
	C2	BAZAN, J. Fernando et al.; Nature; 379:591 (15 Feb. 1996)		
	C3	BOSCHETTI, Egisto; TRENDS in Biotechnology; 20(8):333-337 (Aug. 2002)		
	C4	BURTON, S.C. et al.; Journal of Chromatography A; 814:71-81 (1998)		
	C5	CHEBATH, Judith et al.; European Cytokine Network; 8(4):359-365 (Dec. 1997)		
	C6	CONSTANS, Aileen; The Scientist; pp. 40-42 (21 Jan. 2002)		
	C7	CORBAZ, Anne et al.; The Journal of Immunology; 168(7):3608-3616 (1 Apr. 2002)		
	C8	ENGELMANN, Hartmut et al.; The Journal of Biological Chemistry; 265(3):1531-1536 (25 Jan. 1990)		
	C9	ENGELMANN, Hartmut et al.; The Journal of Biological Chemistry; 264(20):11974-11980 (15 Jul. 1989)		
	C10	GHAYUR, Tariq et al.; Nature; 386:619-623 (10 Apr. 1997)		
	C11	HALABY, D.M. et al.; Journal of Molecular Evolution; 46:389-400 (1998)		
	C12	HALABY, D.M. et al.; Protein Engineering; 12(7):563-571 (1999)		
	C13	HEINRICH, Peter C. et al.; Biochem. J.; 334:297-314 (1998)		
	C14	JONES, Simon A. et al.; The FASEB Journal; 15:43-58 (Jan. 2001)		
	C15	KIM, Soo-Hyun et al.; PNAS; 97(3):1190-1195 (1 Feb. 2000)		



Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	To be assigned (371 of PCT/IL2004/000732)
				I.A. Filing Date	05 August 2004
				First Named Inventor	Boris SCHWARTSBURD
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	3	of	4	Attorney Docket Number	057878-000024

C16	KIM, Soo Hyun et al.; The Journal of Immunology; 166:148-154 (2001)	
C17	KOLLET, Orit et al.; Blood; 94(3):923-931 (1 Aug. 1999)	
C18	McMAHAN, Catherine J. et al.; The EMBO Journal; 10(10):2821-2832 (1991)	
C19	MÜHL, Heiko et al.; Biochemical and Biophysical Research Communications; 267:960-963 (2000)	
C20	NAKAMURA, Kyohshi et al.; Infection and Immunity; 57(2):590-595 (Feb. 1989)	
C21	NAKAMURA, Kyohshi et al.; Infection and Immunity; 61(1):64-70 (Jan. 1993)	
C22	NAKAMURA, Shuji et al.; The Journal of Immunology; 164:3330-3336 (2000)	
C23	NOVICK, D. et al.; FEBS; 314(3):445-448 (Dec. 1992)	
C24	NOVICK, Daniela et al.; Cytokine; 14(6):334-342 (21 Jun 2001)	
C25	NOVICK, Daniela et al.; J. Exp. Med.; 170:1409-1414 (Oct. 1989)	
C26	NOVICK, Daniela et al.; Cell; 77:391-400 (6 May 1994)	
C27	NOVICK, Daniela et al.; Immunity; 10:127-136 (Jan. 1999)	
C28	OKAMURA, Haruki et al.; Nature; 378:88-91 (Nov. 1995)	
C29	OKAMURA, Haruki et al.; Current Opinion in Immunology; 10:259-264 (1998)	
C30	OSBORN, Laurelee et al.; The Journal of Cell Biology; 124(4):601-608 (Feb. 1994)	
C31	PEDERSEN, Bente Klarlund et al.; Journal of Physiology; 536.2:329-337 (2001)	
C32	PORATH, Jerker et al.; Nature; 467:1657-1659 (13 Jun. 1959)	

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	To be assigned (371 of PCT/IL2004/000732)
				I.A. Filing Date	05 August 2004
				First Named Inventor	Boris SCHWARTSBURD
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	4	of	4	Attorney Docket Number	057878-000024

C33	PUREN, Adrian J. et al.; Proc. Natl. Acad. Sci. USA; 96:2256-2261 (Mar. 1999)	
C34	SCHWARTZ, Warren et al.; Journal of Chromatography A; 908:251-263 (2001)	
C35	SIMONET, W.S. et al.; Cell, 89:309-319 (18 Apr. 1997)	
C36	SMITH, Christopher; The Scientist; pp. 14-19 (16 Mar. 1998)	
C37	TSUTSUI, Hiroko et al.; The Journal of Immunology; 157:3967-3973 (1996)	
C38	URUSHIHARA, Naoto et al.; Journal of Pediatric Surgery; 35(3):446-449 (Mar. 2000)	
C39	USHIO, Shimpei et al.; The Journal of Immunology; 156:4274-4279 (1996)	
C40	VIGERS, Guy P.A. et al.; Nature; 386:190-194 (13 Mar. 1997)	
C41	WEATHERLY, Gresham T. et al.; Journal of Chromatography A; 952:99-110 (2002)	
C42	XIANG, Yan et al.; Virology; 257:297-302 (1999)	
C43	YASUDA, HISATAKA et al.; Endocrinology; 139:1329-1337 (1998)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.